azd3161
Nociceptive Pain
AstraZenecaPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Nociceptive Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tapentadol Grünenthal GmbH | Phase 3 | B |
Cntx-6016 Centrexion Therapeutics | Phase 1 | CC |
LIDOCAINE AstraZeneca | Phase 1 | CC |
Cntx-6970 Centrexion Therapeutics | Phase 1 | CC |
FTC-146 Stanford University | Phase 1 | CC |
Esmolol Aretaieion University Hospital | N/A | D |
Same molecule, other indications
azd3161 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →